Participation in the upcoming DiaMedica Therapeutics conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on the development of recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia, today announced that management will participate in its next investor conferences in September.

• HC Wainwright Global Investment ConferenceSeptember 9-11, New York – Management will present in person and participate in one-on-one meetings on Monday, September 9 from 3:00 to 3:30 p.m. ET.
• Lake Street Best Ideas Growth Conference Big 8September 12, New York – Management will participate in individual meetings.

Investors and participants who wish to make an appointment with DiaMedica management can contact their account managers to make an appointment.